GSK and Genmab's Arzerra similar to Rituxan in RA study
This article was originally published in Scrip
Executive Summary
Preliminary results have shown that GlaxoSmithKline and Genmab's intravenous monoclonal antibody Arzerra (ofatumumab) has met the primary endpoint in its first Phase III study in rheumatoid arthritis, yielding similar results to those of Roche's anti-CD20 Rituxan (rituximab),.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.